CD122-directed interleukin-2 treatment mechanisms in bladder cancer differ from αPD-L1 and include tissue-selective γδ T cell activation.
Reyes RM, Deng Y, Zhang D, Ji N, Mukherjee N, Wheeler K, Gupta HB, Padron AS, Kancharla A, Zhang C, Garcia M, Kornepati AVR, Boyman O, Conejo-Garcia JR, Svatek RS, Curiel TJ.
Reyes RM, et al.
J Immunother Cancer. 2021 Apr;9(4):e002051. doi: 10.1136/jitc-2020-002051.
J Immunother Cancer. 2021.
PMID: 33849925
Free PMC article.